Here are five key takeaways:
1. The trial includes 13 sites and 80 patients.
2. The IlluminOss System uses proprietary bone stabilization technology, allowing for fracture fixation through patient-specific intramedullary implants.
3. The system was developed as an alternative to standard-of-care nails and plates.
4. Approved in international markets, the system has been used to treat more than 1,500 patients worldwide.
5. The outcomes data from the trial allow the company to submit a DeNovo marketing application to the FDA.
More articles on devices:
NuVasive, Bioventus, DFINE & more: 17 key notes
Medtech sells 13 ROSA robots in Q4 2016 — 5 highlights
Dr. Nicole Ehrhart’s preclinical study affirms AlloStem Cellular Bone Allograft effectiveness: 5 key takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
